MEDIA RELEASE

QT VASCULAR ACHIEVES NET PROFIT OF US$15.2 MILLION IN 2Q2016

Highlights:

- **Gross profit improved to US$1.1 million on increase in direct sales and better margins earned by the Group's direct sales team**
- **The Group reversed US$24.1 million of provision for legal liability, after the earlier district court judgement was reversed by the United States Court of Appeals for the Federal Circuit**
- **Chocolate® family of products is positioned for continued growth supported by the rapid adoption of drug-coated balloons in the US market**

SINGAPORE, 4 August 2016 – QT Vascular Ltd., together with its subsidiaries ("**QT Vascular**" or the "**Group**"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, achieved revenue of US$2.4 million for the three months ended 30 June 2016 ("**2Q2016**"), from US$3.3 million a year ago. Majority of the Group's revenue in 2Q2016 comes from Chocolate® PTCA Balloon Catheter ("**Chocolate PTCA**"). The number of United States ("**US**") hospitals using Chocolate PTA has increased between 2Q2016 and three months ended 30 June 2015 ("**2Q2015**"), and the amount of sales made by the Group's direct sales team saw an increase of 138.8% in revenue for our Chocolate® PTA Balloon Catheter ("**Chocolate PTA**"), Glider™ PTCA Balloon Catheter and Chocolate PTCA products when compared with 2Q2015. Notwithstanding this, there was an overall decrease in sales mainly due to lower purchases of our Chocolate PTA product by Cordis, Inc. following channel inventory levels reduction of Chocolate PTA.

The Group recorded a gross profit of US$1.1 million or 46.1% of revenue in 2Q2016 as compared to a gross profit of US$0.4 million or 13.0% of revenue in 2Q2015. The increase in gross profit margin was due to the increased contribution by our direct sales team which generates better margins.

In line with the commendable sales performance by the Group's direct sales team, the Group's sales and marketing expenses increased from US$2.5 million in 2Q2015 to US$2.7 million in 2Q2016. The Group also incurred higher research and development expenses of US$2.1 million during the quarter, as it continues to further develop its peripheral drug-coated balloon, Chocolate Touch®. The Group's overall finance costs also increased from US$0.6 million in 2Q2015 to US$3.2 million in 2Q2016 due mainly to the interest expenses on the convertible and exchangeable notes and foreign exchange losses.

On 21 July 2016, the United States Court of Appeals for the Federal Circuit ("**Federal Circuit**") reversed an earlier district court judgement against the Group, in relation to the litigation with AngioScore, Inc., which resulted in the reversal for provision for legal liability amounting to US$24.1 million.

As a result of the above, the Group recorded a net profit of US$15.2 million for 2Q2016, compared with a net loss of US$6.4 million for 2Q2015.

Dr. Eitan Konstantino, Ph.D., Chief Executive Officer of QT Vascular said, ***"We are encouraged with the progress made by our direct sales team and the improvement in gross profit. We continue our efforts to advance the Drug coated portfolio towards regulatory approvals to tap into the booming US Drug coated balloons market, to increase the direct sales of our existing products and explore strategic options."***

Financial Position

The Group reverted into a net asset position of US$3.3 million following the reversal for provision for legal liability as a result of the ruling from the Federal Circuit. The Group's negative working capital of US$9.8 million as at 30 June 2016 is mainly due to the convertible and exchangeable notes of US$8.2 million and the financial instruments in relation to the fair value of the convertible and exchangeable notes of US$1.5 million.

On 19 July 2016, the Company announced that it had entered into a non-binding term sheet with a third party for the potential transaction(s) for the Group's Chocolate PTA assets. The international investment bank appointed by the Company as its strategic advisor, Nomura Securities International, Inc., continues to provide financial and market-related advice and assistance related to strategic options for the Group.

Business Outlook

The adoption of drug-coated balloons ("**DCB**") in Europe and the US is rapidly increasing. With two DCBs approved for use by the US Food and Drug Administration ("**FDA**") in the US, backed by continued strong clinical data, the use of DCBs is expected to continue growing. This is a positive development for the market, and it reflects the growth potential of this large market. In 2016, it is estimated that the use of DCBs may surpass 20% of procedures in the femoral-popliteal arteries.

Despite the near-term challenges, the continued adoption of the Group's Chocolate® platform of products is expected to drive growth. These include the Chocolate® PTCA device in the US, Chocolate Touch® in Europe and Glider PTCA in Japan.

The strong clinical results for both Chocolate Touch® and Chocolate Heart™ is likely to bode well for the Group in the long term. The Group had also made the IDE submission in 2Q2016 to the FDA for Chocolate Touch®, as it moves towards being one of the few suppliers in the fast-growing US market for DCBs.

~~ End ~~

This press release is to be read in conjunction with the Company's announcement posted on the SGX website on 4 August 2016.

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0 | Bloomberg: QTVC:SP | Reuters: QTVA:SI)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC ("**TriReme Medical**"), based in Pleasanton, California. TriReme Medical's range of percutaneous transluminal angioplasty ("**PTA**") and percutaneous transluminal coronary angioplasty ("**PTCA**") products include (i) Chocolate® PTA Balloon Catheter, (ii) Chocolate® PTCA Balloon Catheter, (iii) GliderXtreme™ PTA Balloon Catheter, (iv) GliderfleX® PTA Balloon Catheter and (v) Glider™ PTCA Balloon Catheter, all of which have the CE mark that allows them to be sold in Europe, and FDA clearance to be sold in the United States. Additionally, the GliderXtreme™ PTA Balloon Catheter has the regulatory clearance in China and Japan, while the Glider™ PTCA Balloon Catheter has the regulatory clearance in Japan. These products are sold by the Group's direct sales team and through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Cardinal Health, Inc.), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

The Group's drug coated version of the Chocolate® PTA Balloon Catheter, Chocolate Touch®, and the Chocolate® PTCA Balloon Catheter, Chocolate Heart™, have the CE mark that allows them to be sold in Europe.

For more information, please visit the company website at www.qtvascular.com

---

Issued on behalf of **QT VASCULAR LTD.** by:

WATERBROOKS CONSULTANTS PTE LTD
Tel: +65 6100 2228

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg
Ms Angeline Cheong	(M): +65 9666 0977	angeline@waterbrooks.com.sg

---

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited {"**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.